NYSE:DGXHealthcare
How Investors May Respond To Quest Diagnostics (DGX) City of Hope ctDNA MRD Trial Collaboration
On 16 April 2026, Quest Diagnostics announced that City of Hope is using its Haystack MRD circulating-tumor DNA test in multi-year clinical trials for about 500 solid-tumor cancer patients across fourteen U.S. sites, aiming to detect minimal residual disease, monitor treatment response, and identify recurrence earlier than standard imaging.
This collaboration highlights Quest’s growing role in advanced oncology diagnostics, using longitudinal ctDNA measurements to support more personalized...